Correspondence 0001493152-24-049269 from Regen BioPharma Inc (RGBP)
Regen BioPharma Inc
Date: Dec. 9, 2024 · CIK: 0001589150 · Accession: 0001493152-24-049269
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12505
Letter
Via Edgar Securities and Exchange Commission December 9, 2024 Offering Statement on Form 1-A/A File No.: 024-12505
Re: Regen BioPharma, Inc.
Dear Mr. McCann and Ms. Hamill
Regen Biopharma, Inc. (the “Company”) hereby requests qualification of the above-referenced offering statement at 9:30 a.m., Eastern Time, on December 10, 2024, or as soon thereafter as is practicable.
In connection with the foregoing request, the Company hereby confirms and acknowledges that:
1. should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3. the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
The Company affirms it has been advised by at least one state that the offering has been declared “Effective or Cleared for Sale” upon qualification by the SEC.
If you should require any additional information or clarification, please do not hesitate to contact me.
Very truly yours,
/s/
David R.Koos
Show Raw Text
CORRESP
1
filename1.htm
Via
Edgar
Securities
and Exchange Commission
100
F. Street, NE
Washington,
D.C. 20549-7410
Attn:
Joe McCann
Lauren Hamill
December
9, 2024
Re:
Regen
BioPharma, Inc.
Offering
Statement on Form 1-A/A
File
No.: 024-12505
Dear
Mr. McCann and Ms. Hamill
Regen
Biopharma, Inc. (the “Company”) hereby requests qualification of the above-referenced offering statement at 9:30 a.m., Eastern
Time, on December 10, 2024, or as soon thereafter as is practicable.
In
connection with the foregoing request, the Company hereby confirms and acknowledges that:
1. should
the Commission or the staff, acting pursuant to delegated authority, qualify the filing,
it does not foreclose the Commission from taking any action with respect to the filing;
2. the
action of the Commission or the staff, acting pursuant to delegated authority, in qualifying
the filing, does not relieve the Company from its full responsibility for the adequacy and
accuracy of the disclosure in the filing; and
3. the
Company may not assert staff comments and/or qualification as a defense in any proceeding
initiated by the Commission or any person under the federal securities laws of the United
States.
The
Company affirms it has been advised by at least one state that the offering has been declared “Effective or Cleared for Sale”
upon qualification by the SEC.
If
you should require any additional information or clarification, please do not hesitate to contact me.
Very truly yours,
/s/
David R.Koos
David R. Koos,
Chairman & CEO